The ATTAIN study: Bronchodilatory effect of aclidinium bromide in chronic obstructive pulmonary disease (COPD). David Singh, Eric D. Bateman, Paul W. Jones. The ATTAIN study: Safety and tolerability of aclidinium bromide in chronic obstructive pulmonary disease. Eric D. Bateman, David Singh, Paul W. Jones, Alvar. This paper presents results from a phase III study of longer duration (Aclidinium To Treat Airway obstruction In COPD patieNts; ATTAIN), which.
|Published (Last):||11 May 2008|
|PDF File Size:||8.97 Mb|
|ePub File Size:||20.73 Mb|
|Price:||Free* [*Free Regsitration Required]|
Cochrane Database Syst Rev.
Pharmacokinetics and safety of aclidinium bromide in younger and elderly patients with chronic obstructive pulmonary disease. In the ACCORD COPD I study, 31 night-time and morning COPD symptoms were all significantly reduced among patients treated with aclidinium compared with those who received placebo Figure 5and the impact of breathlessness on early morning activities was also significantly reduced with aclidinium versus studyy Figure 6.
Well tolerated, no anticholinergic side acildinium reported, no clinical effect on EKG parameters. Preference, satisfaction and errors with two dry powder inhalers in patients with COPD. In acidinium studies, these improvements were sustained for up to 52 weeks. Week 12 trough FEV 1 change from baseline vs placebo: As noted in the current GOLD guidelines, tiotropium, aclidinium, and glycopyrronium can all be considered as appropriate options for maintenance treatment in the stable COPD patient.
Clinical potential of aclidinium bromide in chronic obstructive pulmonary disease
Glycopyrronium bromide is a synthetic quaternary ammonium compound, which has been used for many years to reduce secretions and block cardiac vagal reflexes before surgery. Improvement in symptoms and rescue medication use with aclidinium bromide in patients with chronic obstructive pulmonary disease: Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: Once-daily glycopyrronium bromide, a long-acting muscarinic antagonist, for chronic obstructive pulmonary disease: It has been extensively studied in patients with COPD — a recent Cochrane review identified 22 studies of good methodological quality that had enrolled 23, participants with COPD.
Abstract Three long-acting muscarinic antagonists LAMAs are now available in Europe, providing clinicians and patients with a choice of interventions, which is important in COPD, which is clinically a heterogeneous disease. Support Center Support Center. Adverse events reported by seven patients receiving aclidinium, eight receiving placebo, and three receiving tiotropium Most common AE was COPD exacerbation three patients all receiving placebo. The subject of this review is a third Acliinium, aclidinium bromide, which was approved as a twice-daily maintenance bronchodilator treatment.
Global Initiative for Chronic Obstructive Lung Disease [webpage on the Internet] Xclidinium strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease [updated ] [Accessed December 12, ]. Efficacy and safety of twice-daily aclidinium bromide in COPD patients: The safety profile of aclidinium was comparable to placebo. Expert Opin Drug Deliv. However, the rate of decline in FEV 1 — the primary outcome of the trial — was not significantly reduced by the use of tiotropium.
Eur Respir JOctober The low systemic bio-availability of aclidinium may be an advantage, but more data are needed, as this is a class of drugs with a generally low side-effect rate.
European Medicines Agency; A new user cohort study comparing the safety of long-acting inhaled bronchodilators in COPD. Global Initiative for Chronic Obstructive Lung Disease [webpage on the Internet] Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease [updated Jan ] [Accessed Axlidinium 12, ].
Published online Mar The author and his institution have received consulting and lecture fees from Almirall S. Safety and pharmacokinetics of multiple doses of aclidinium bromide administered twice daily in healthy volunteers. In conclusion, when considering new inhaled drugs, it is important to look beyond the chemical entity and its pharmacology.
Safety and pharmacokinetics of multiple doses of aclidinium bromide, a novel long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease, in healthy participants. Furthermore, a higher proportion of patients treated with aclidinium achieved the MCID in each of these measures, compared with placebo. Professor Paul Jones is the guarantor for this article, and takes responsibility for the integrity of the work as a whole.
Reproduced with permission of the European Respiratory Society: Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: Twice-daily aclidinium bromide in COPD patients: Reduced COPD exacerbations associated with aclidinium bromide versus placebo: Aclidinium bromide for stable chronic obstructive pulmonary disease. Breathlessness, health status, and COPD symptoms with aclidinium Significant improvements were seen in breathlessness, health status, and COPD symptoms in the pivotal trials.
Three long-acting muscarinic antagonists LAMAs are now available in Europe, providing clinicians and patients with a choice of interventions, which is important in COPD, which is clinically a heterogeneous disease.
Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study.
Another new once-daily LAMA, glycopyrronium, has also been shown to improve health status and reduce exacerbations, and is well tolerated.
Dosing regimens and inhaler performance may be equally important in determining relative advantages of one drug over another. This article has been cited alidinium other articles in PMC.
Tiotropium has been widely used over the last decade as once-daily maintenance therapy in stable COPD. Effect of formoterol alone and in combination with aclidinium on agtain in dogs. The impact of tiotropium on mortality and exacerbations when added to inhaled corticosteroids and long-acting beta-agonist therapy in COPD.
Summary review of regulatory action. Data reported as least squares mean standard error. National Center for Biotechnology InformationU.
The BID dosing does not appear to be a disadvantage compared to the QD regimes of tiotropium and glycopyrronium, since it may confer attsin overnight bronchodilation that may be particularly beneficial for patients with significant night and morning symptoms.
Pooled data showed exacerbation frequency was significantly reduced with aclidinium versus placebo.
Significant improvements were seen in breathlessness, health status, and COPD symptoms in the pivotal trials. Aclidinium bromide provides long-acting bronchodilation in patients with COPD.
Aclidinium has been extensively evaluated in patients with COPD Table 1 29 — 39 and has also been the subject of a recent Cochrane systematic review.